Observational cohort study focused on treatment continuity of patients (pts) treated with XELOX plus bevacizumab (BV) for previously untreated metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Kotaka, Masahito
Ikeda, Husao
Ikumoto, Taro
Tsuzie, Masaki
Yoshioka, Shinichi
Nakamoto, Yoshihiko
Ishii, Takaaki
Goto, Saori
Itami, Atsushi
Kato, Takeshi
机构：
[1] Sano Hosp, Kobe, Hyogo, Japan
[2] Kouka Publ Hosp, Dept Surg, Kobe, Hyogo, Japan
[3] Sano Hosp, Gastrointestinal Ctr, Kobe, Hyogo, Japan
[4] Hyogo Prefectural Nishinomiya Hosp, Dept Surg, Kobe, Hyogo, Japan
[5] Kobe City Med Ctr West Hosp, Dept Surg, Kobe, Hyogo, Japan
[6] Kobe Ekisaikai Hosp, Dept Surg, Kobe, Hyogo, Japan
[7] Saiseikai Noe Hosp, Dept Surg, Osaka, Japan
[8] Nishikobe Med Ctr, Dept Surg, Kobe, Hyogo, Japan
[9] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.661
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
    Kotaka, Masahito
    Ikeda, Fusao
    Tsujie, Masaki
    Yoshioka, Shinichi
    Nakamoto, Yoshihiko
    Ishii, Takaaki
    Kyogoku, Takahisa
    Kato, Takeshi
    Tsuji, Akihito
    Kobayashi, Michiya
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 4113 - 4120
  • [2] Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Kasubhai, Saifuddin M.
    Bendell, Johanna C.
    Kozloff, Mark
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [4] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 250 - 251
  • [5] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Ashkenazi, A.
    Royer-Joo, S.
    Portera, C. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Steffens, Claus-Christoph
    Brugger, Wolfram
    Hapke, Gunnar
    Illerhaus, Gerald
    Bluemner, Ernst
    Bokemeyer, Carsten
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [7] Characteristics of long-versus short-surviving patients (Pts): An analysis of the ARIES Observational Cohort Study (OCS) of bevacizumab (BV)-treated pts with metastatic colorectal cancer (mCRC).
    Kozloff, Mark
    Grothey, Axel
    Bendell, Johanna C.
    Cohn, Allen Lee
    Bekaii-Saab, Tanios S.
    Roach, Nancy
    Flick, Elizabeth Dawn
    Mun, Yong
    Fish, Susan Meredith
    Laeufle, Rita
    Sommer, Nicolas
    Hurwitz, Herbert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] A PHASE II STUDY OF CAPECITABINE, IRINOTECAN, AND BEVACIZUMAB (XELIRI-A) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Chen, E.
    Welch, S.
    Kryzanowska, M.
    Mackay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 36 - 37
  • [10] A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Chen, E. X.
    Welch, S.
    Krzyzanowska, M.
    MacKay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345